Kissei Pharmaceutical Co., Ltd. (4547)

Name: Kissei Pharmaceutical Co., Ltd. (4547) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-10-02

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia.

Cifras clave

Capitalización bursátil: JPY 155 billion
Ingresos (ejercicio cerrado en 2026-03-31): JPY 97.4B
Beneficio neto: JPY 13.8B
Margen bruto: 47.0%
Margen neto: 14.1%

Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Ingresos totales	JPY 97.4B	JPY 88.3B	JPY 75.6B	JPY 67.5B
Beneficio bruto	JPY 45.8B	JPY 44.1B	JPY 37.3B	JPY 32.4B
Ingresos operativos (EBIT)	(JPY 2.9B)	JPY 5.8B	JPY 4.0B	(JPY 1.1B)
Ingresos netos	JPY 13.8B	JPY 12.0B	JPY 11.2B	JPY 10.5B

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 4547. /companies/us/4547

Empresas similares

4521 · Kaken Pharmaceutical Co., Ltd.

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.